The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers

Abstract

Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells generated from myeloid cell precursors in the bone marrow. MDSCs appear almost exclusively in pathological conditions, such as tumor progression and various inflammatory diseases. The leading function of MDSCs is their immunosuppressive ability, which plays a crucial role in tumor progression and metastasis through their immunosuppressive effects. Since MDSCs have specific molecular features, and only a tiny amount exists in physiological conditions, MDSC‐targeted therapy has become a promising research direction for tumor treatment with minimal side effects. In this review, we briefly introduce the classification, generation and maturation process, and features of MDSCs, and detail their functions under various circumstances. The present review specifically demonstrates the environmental specificity of MDSCs, highlighting the differences between MDSCs from cancer and healthy individuals, as well as tumor‐infiltrating MDSCs and circulating MDSCs. Then, we further describe recent advances in MDSC‐targeted therapies. The existing and potential targeted drugs are divided into three categories, monoclonal antibodies, small‐molecular inhibitors, and peptides. Their targeting mechanisms and characteristics have been summarized respectively. We believe that a comprehensive in‐depth understanding of MDSC‐targeted therapy could provide more possibilities for the treatment of cancer.

Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications

“…Delving further, there are prospective avenues yet to be explored, suggesting potential interventions based on the observed TIME heterogeneity across different molecular subtypes of TNBC. In the case of LAR tumors, MDSC-targeted therapies could be of potential value, including inhibition of MDSC function or recruitment into the TIME, inducing their differentiation or mediating their depletion [ 56 , 57 ]. In patients with the MSL subtype, featuring a high number of M2 TAMs, inhibition of the chemokine (C-C motif) ligand 2 (CCL2)/circulating chemokine-receptor-type 2 (CCR2) axis could decrease the recruitment of bone marrow mononuclear cells, subsequently reducing macrophage infiltration in the breast [ 58 , 59 ].…”

Myeloid-Derived Suppressor Cells mediate hepatocyte proliferation and immune suppression during liver regeneration following resection

“…Myeloid Derived Suppressor Cells (MDSCs) represent a heterogeneous population of immature myeloid cells characterized by the cell surface markers CD11b and Gr1 (Ly6G/Ly6C) in mouse and by HLA-DR-, CD11b, CD14/15 and more in human (12)(13). Notably, MDSCs have emerged as critical immune regulators in various contexts including cancer and other developmental processes such as wound healing, placenta formation, and more (14)(15)(16)(17)(18)(19)(20)(21)(22)(23). We have previously showed that MDSCs play key roles in the early stages of liver regeneration.…”